文献速递艾滋病与性传播感染

HIV-1 O组与M组感染者抗逆转录病毒治疗的免疫病毒学及临床应答比较

Comparative Immunovirological and Clinical Responses to Antiretroviral Therapy Between HIV-1 Group O and HIV-1 Group M Infected Patients.
PubMed 文献 · Clin Infect Dis · 2020-01-01

48周时两组不可测病毒载量比例无显著差异,O组基线病毒载量低1 log;CD4增益在M组较高但校正后不显著。结论为两组免疫病毒学及临床应答相似。

要点

  • HIV-1 O组与M组在48周病毒学应答无显著差异
  • O组基线病毒载量较M组低1 log
  • CD4增益差异在校正基线病毒载量后不显著

核心结论

  • HIV-1 O组与M组患者对标准化cART的免疫病毒学及临床应答相似。
  • O组变异株基线复制水平显著较低,提示其特有病毒学特性与病理生理机制需进一步研究。

研究设计与样本

  • 开放非随机研究,比较初治HIV-1 O组与M组患者,按1:2配对匹配。
  • 方案为2种核苷类逆转录酶抑制剂+1种利托那韦增效蛋白酶抑制剂。
  • 主要终点为48周时血浆病毒载量不可测(阈值60 copies/mL)的比例。

主要发现

  • O组基线平均病毒载量较M组显著低1 log。
  • 48周时两组不可测病毒载量比例无显著差异,24周和96周差异亦不显著。
  • 48周和96周CD4增益在M组较高,但校正匹配标准和基线病毒载量后不显著。

关键数值与推荐

  • 病毒载量不可测阈值定义为60 copies/mL。
  • 主要终点评估时间为第48周。
  • 次要终点包括第24周和第96周病毒载量不可测比例及CD4变化。

临床怎么用

  • HIV-1 O组感染者可参照M组使用标准化cART方案。
  • 临床监测中需注意O组基线病毒载量可能较低。
  • CD4恢复差异需结合基线病毒载量综合解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Little is known about impact of genetic divergence of human immunodeficiency virus type 1 group O (HIV-1/O) relative to HIV-1 group M (HIV-1/M) on therapeutic outcomes. We aimed to determine if responses to standardized combination antiretroviral therapy (cART) were similar between groups despite strain divergence. METHODS: We performed an open nonrandomized study comparing the immunological, virological, and clinical responses to cART based on 2 nucleoside reverse transcriptase inhibitors plus 1 ritonavir-boosted protease inhibitor, in naive and paired HIV-1/O vs HIV-1/M infected (+) patients (ratio 1:2), matched on several criteria. The primary endpoint was the proportion of patients with undetectable plasma viral load (pVL, threshold 60 copies/mL) at week (W) 48. Secondary endpoints were the proportion of patients with undetectable pVL at W24 and W96 and CD4 evolution between baseline and W24, W48, and W96. RESULTS: Forty-seven HIV-1/O+ and 94 HIV-1/M+ patients were included. Mean pVL at baseline was significantly lower by 1 log for HIV-1/O+ vs HIV-1/M+ patients. At W48, no significant difference was observed between populations with undetectable pVL and differences at W24 and W96 were not significant. A difference in CD4 gain was observed in favor of HIV-1/M at W48 and W96, but this was not significant when adjusted on both matched criteria and pVL at baseline. CONCLUSIONS: Our data demonstrate similar immunovirological and clinical response between HIV-1/O+ and HIV-1/M+ patients. They also reveal significantly lower baseline replication for HIV-1/O variants, suggesting specific virological properties and physiopathology that now need to be addressed. CLINICAL TRIALS REGISTRATION: NCT00658346.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Kouanfack C, Unal G, Schaeffer L, et al. Comparative Immunovirological and Clinical Responses to Antiretroviral Therapy Between HIV-1 Group O and HIV-1 Group M Infected Patients. Clin Infect Dis. 2020. PMID: 31063537. doi:10.1093/cid/ciz371

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。